Sangamo Therapeutics, Inc. (the Company) received a notification from Nasdaq on April 28, 2026, regarding its determination to delist the Company's common stock due to a failure to meet the minimum bid price requirement. The Company's common stock was suspended from trading on Nasdaq and began trading on the OTCQB Venture Market on May 5, 2026. Following the filing of a voluntary petition for bankruptcy under Chapter 11 on June 24, 2026, the Company's common stock began trading on the OTCID Basic Market under the symbol SGMOQ. The Company's appeal of the Nasdaq delisting determination is still pending. On June 25, 2026, the Audit Committee of the Board of Directors terminated the engagement of Ernst & Young LLP (EY) as the Company's independent registered public accounting firm. EY's reports for fiscal years ended December 31, 2024, and December 31, 2025, included an explanatory paragraph regarding the Company's ability to continue as a going concern. There were no disagreements with EY on accounting principles or practices, financial statement disclosure, or auditing scope or procedure during the relevant periods. EY has confirmed agreement with the statements made in the 8-K filing regarding the change in accountants.